Last updated on July 2018

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk


Brief description of study

Comparison of survival in patients with or without a matched donor at 36 months

Detailed Study Description

Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation.

Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.

Clinical Study Identifier: NCT02757989

Contact Investigators or Research Sites near you

Start Over

Jérôme Cornillon, MD

Institut de canc rologie Lucien Neuwirth
Saint-Priest-en-Jarez, France
  Connect »